Cluster Headache Clinical Trial
Official title:
A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache
NCT number | NCT01298921 |
Other study ID # | 2010-0205 |
Secondary ID | |
Status | Terminated |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | January 2011 |
Est. completion date | July 2012 |
Verified date | April 2019 |
Source | Geisinger Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cluster headache is a disorder marked by frequent attacks of short-lasting, severe,
unilateral head pain with associated autonomic symptoms. It is the most severe head pain
syndrome known. Currently, the two most common treatments for cluster headaches are inhaled
oxygen and injectable sumatriptan. These treatments do not work for all cluster headache
patients, and patients who smoke may eventually develop contraindication to triptans. New
treatment options are needed.
An alternative method of oxygen delivery (as opposed to continuous flow) uses a demand valve
that is controlled by respiration rate, allowing increased oxygen flow in response to
increased demand. This system may be more efficacious at stopping a cluster headache attack
than the currently prescribed oxygen delivery system.
This study will compare the effectiveness of oxygen delivered via demand valve versus
continuous high flow oxygen via non-rebreather face mask in the acute treatment of a cluster
headache attack. All patients will treat one cluster headache with each of the 2 treatment
methods.
Status | Terminated |
Enrollment | 4 |
Est. completion date | July 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Men or women 18 to 65 with history of moderate severe or very severe cluster headaches and currently in a cluster headache period or cycle are included. Exclusion Criteria: - Subjects who have a history of chronic obstructive lung disease, those who have major neurologic disorders other than cluster headaches, those with a history of syncope, or lightheadedness with hyperventilation and pregnant women are excluded. |
Country | Name | City | State |
---|---|---|---|
United States | Geisinger Wyoming Valley | Wilkes-Barre | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Geisinger Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction in Headache Pain | Headache response after 30 minutes of oxygen treatment. Headache response is defined as a reduction in headache pain intensity from moderate, severe, or very severe pain to mild or no pain. | 30 minutes | |
Secondary | Headache Relief and Pain Free | Percentage of patients with no pain after 30 minutes of treatment Headache relief and pain free at other time points (5 to 60 minutes) Reduction of autonomic symptoms at 30 minutes Any difference in treatment response between episodic and chronic cluster headache patients (if patient #'s allow) Rescue medication use Cluster headache recurrence by 24 hours post oxygen treatments Patient satisfaction with treatment response compared with prior oxygen treatment if have utilized8.Likelihood of choosing this technique again to treat a cluster headache attack |
5 to 60 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05264714 -
Cluster Headache Treatment With Rimegepant
|
Phase 2 | |
Completed |
NCT01677026 -
Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
|
||
Terminated |
NCT00203190 -
A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache
|
Phase 4 | |
Terminated |
NCT04570475 -
High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache
|
Phase 3 | |
Completed |
NCT04066023 -
Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04353505 -
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
|
Phase 1 | |
Completed |
NCT02019017 -
Botox Injection in Treatment of Cluster Headache
|
Phase 1/Phase 2 | |
Completed |
NCT05153876 -
An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
|
||
Recruiting |
NCT05324748 -
Repeated GON Injections in CCH
|
Phase 3 | |
Completed |
NCT02782533 -
DBS of the Third Ventricle for Cluster Headache and Obesity
|
N/A | |
Completed |
NCT04179266 -
Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache
|
Phase 1/Phase 2 | |
Recruiting |
NCT04406259 -
Atrioventricular Block and Cluster Headache (SEVA)
|
Phase 4 | |
Recruiting |
NCT06206772 -
Resting State Functional Connectivity in Cluster Headache
|
||
Recruiting |
NCT03944876 -
Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache
|
Phase 3 | |
Not yet recruiting |
NCT05857098 -
Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
|
||
Recruiting |
NCT02910323 -
The Will Erwin Headache Research Center - Cluster Headache Study
|
||
Terminated |
NCT00458770 -
Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks
|
N/A | |
Completed |
NCT00662935 -
Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH)
|
N/A | |
Active, not recruiting |
NCT03511846 -
Pain Biomarker Study
|
Phase 1 | |
Completed |
NCT00184587 -
Prophylactic Treatment of Episodic Cluster Headache
|
Phase 2 |